ITRACONAZOLE
ANTIFUNGALS-SYSTEMIC · TOENAIL ONYCHOMYCOSIS ·+4
ASCEND LABORATO
Drug class
Antifungal - Azoles Systemic
Systemic azole antifungals are synthetic antimycotic agents administered orally or parenterally to manage invasive, mucosal, and endemic fungal infections. Read more about Antifungal - Azoles Systemic
131 drugs in this class 79 manufacturers
Drugs in Antifungal - Azoles Systemic
FLUCONAZOLE-NACL (fluconazole in sodium chloride, iso-osmotic)
ANTIFUNGALS-SYSTEMIC · ORAL CANDIDIASIS ·+9
Hospira
ITRACONAZOLE
ANTIFUNGALS-SYSTEMIC · TOENAIL ONYCHOMYCOSIS ·+4
NORTHSTAR RX LL
FLUCONAZOLE
ANTIFUNGALS-SYSTEMIC · ORAL CANDIDIASIS ·+11
ZYDUS PHARMACEU
ITRACONAZOLE
ANTIFUNGALS-SYSTEMIC · OROPHARYNGEAL CANDIDIASIS ·+1
PATRIOT PHARMAC
ITRACONAZOLE
ANTIFUNGALS-SYSTEMIC · OROPHARYNGEAL CANDIDIASIS ·+1
Amneal Pharmaceuticals
ITRACONAZOLE
ANTIFUNGALS-SYSTEMIC · TOENAIL ONYCHOMYCOSIS ·+4
TORRENT PHARMAC
FLUCONAZOLE
ANTIFUNGALS-SYSTEMIC · ORAL CANDIDIASIS ·+11
RISING PHARM
KETOCONAZOLE
ANTIFUNGALS-SYSTEMIC · COCCIDIOIDOMYCOSIS ·+4
STRIDES PHARMA
Filter & compare in the drug finder →
Opens the drug finder with Antifungal - Azoles Systemic preselected. Add indication or manufacturer filters there.
Systemic azole antifungals are synthetic antimycotic agents administered orally or parenterally to manage invasive, mucosal, and endemic fungal infections.
They exert their therapeutic effect by inhibiting the fungal cytochrome P450–dependent enzyme 14-alpha-demethylase, which blocks the conversion of lanosterol to ergosterol, thereby disrupting fungal cell membrane stability and inhibiting cellular growth.
Clinically, these agents—primarily triazoles such as fluconazole, itraconazole, voriconazole, and posaconazole—serve as essential therapies for systemic candidiasis, invasive aspergillosis, cryptococcal meningitis, and endemic mycoses including blastomycosis, histoplasmosis, and coccidioidomycosis, as well as for antifungal prophylaxis in immunocompromised hosts.
-
drugs.com
Systemic azole antifungals are synthetic antimycotic agents administered orally or parenterally to manage invasive, mucosal, and endemic fungal infections They exert their therapeutic effect by inhibiting the fungal cytochrome P450–dependent enzyme 14-alpha-demethylase, which blocks the conversion of lanosterol to ergosterol, thereby disrupting fungal cell membrane stability and inhibiting cellular growth Clinically, these agents—primarily triazoles such as fluconazole, itraconazole, voriconazol...
-
researchgate.net
Systemic azole antifungals are synthetic antimycotic agents administered orally or parenterally to manage invasive, mucosal, and endemic fungal infections
-
nih.gov
Systemic azole antifungals are synthetic antimycotic agents administered orally or parenterally to manage invasive, mucosal, and endemic fungal infections
-
fungaleducation.org
They exert their therapeutic effect by inhibiting the fungal cytochrome P450–dependent enzyme 14-alpha-demethylase, which blocks the conversion of lanosterol to ergosterol, thereby disrupting fungal cell membrane stability and inhibiting cellular growth
-
cdc.gov
They exert their therapeutic effect by inhibiting the fungal cytochrome P450–dependent enzyme 14-alpha-demethylase, which blocks the conversion of lanosterol to ergosterol, thereby disrupting fungal cell membrane stability and inhibiting cellular growth
-
nih.gov
Clinically, these agents—primarily triazoles such as fluconazole, itraconazole, voriconazole, and posaconazole—serve as essential therapies for systemic candidiasis, invasive aspergillosis, cryptococcal meningitis, and endemic mycoses including blastomycosis, histoplasmosis, and coccidioidomycosis, as well as for antifungal prophylaxis in immunocompromised hosts
-
fda.gov
Clinically, these agents—primarily triazoles such as fluconazole, itraconazole, voriconazole, and posaconazole—serve as essential therapies for systemic candidiasis, invasive aspergillosis, cryptococcal meningitis, and endemic mycoses including blastomycosis, histoplasmosis, and coccidioidomycosis, as well as for antifungal prophylaxis in immunocompromised hosts
-
fda.gov
Clinically, these agents—primarily triazoles such as fluconazole, itraconazole, voriconazole, and posaconazole—serve as essential therapies for systemic candidiasis, invasive aspergillosis, cryptococcal meningitis, and endemic mycoses including blastomycosis, histoplasmosis, and coccidioidomycosis, as well as for antifungal prophylaxis in immunocompromised hosts
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.